• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Mereo BioPharma Group plc (Amendment)

    2/14/24 2:11:26 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MREO alert in real time by email
    SC 13G/A 1 rocksprings-mreo123123a3.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*



    MEREO BIOPHARMA GROUP PLC

    (Name of Issuer)

     

    Ordinary Shares, nominal value £0.003, per ordinary share

    (Title of Class of Securities)

     

    589492107**

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 589492107 has been assigned to the American Depositary Receipts (“ADRs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “MREO.” Each ADR represents 5 Ordinary Shares.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  589492107
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    39,919,255 ordinary shares (represented by 7,983,851 ADRs)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    39,919,255 ordinary shares (represented by 7,983,851 ADRs)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    39,919,255 ordinary shares (represented by 7,983,851 ADRs)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.69%
    12
    TYPE OF REPORTING PERSON
     
    IA
     


     

    CUSIP No.  589492107
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Master Fund LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    35,375,000 ordinary shares (represented by 7,075,000 ADRs)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    35,375,000 ordinary shares (represented by 7,075,000 ADRs)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    35,375,000 ordinary shares (represented by 7,075,000 ADRs)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.04%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

    CUSIP No.  589492107
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    39,919,255 ordinary shares (represented by 7,983,851 ADRs)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    39,919,255 ordinary shares (represented by 7,983,851 ADRs)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    39,919,255 ordinary shares (represented by 7,983,851 ADRs)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.69%
    12
    TYPE OF REPORTING PERSON
     
    OO; HC

     


     

     

    CUSIP No. 589492107
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Mereo BioPharma Group Plc (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices

    Fourth Floor, One Cavendish Place

    London W1G 0QF

    United Kingdom

    Item 2.(a) Names of Person Filing

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    i. Rock Springs Capital Management LP (“RSCM”);

    ii. Rock Springs Capital Master Fund LP (“Master Fund”); and

    iii. Rock Springs Capital LLC (“RSC”)

     

    This Statement relates to Shares (as defined herein) held directly by the Rock Springs Capital Master Fund LP, which is a Cayman Island exempted limited partnership, and Four Pines Master Fund LP (“Four Pines”), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to each of the Rock Springs Capital Master Fund LP (the “Master Fund”) and Four Pines. RSC is the general partner of RSCM.

      

    (b) Address of Principal Business Office, or, if none, Residence

    Rock Springs Capital Management LP and Rock Springs Capital LLC

    650 South Exeter, Suite 1070

    Baltimore, MD 21202

     

    Rock Springs Capital Master Fund

    c/o Walkers Corporate Limited

    190 Elgin Avenue

    George Town, Grand Cayman, KY1-9008, Cayman Islands

     

    (c) Citizenship

    Rock Springs Capital Management LP - Delaware

    Rock Springs Capital Master Fund LP - Cayman Islands

    Rock Springs Capital LLC - Delaware

    (d) Title of Class of Securities

    Ordinary Shares, nominal value £0.003, per ordinary share (the “Shares”)

    (e) CUSIP No.:

    There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 589492107 has been assigned to the American Depository Receipts (“ADRs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “MREO.” Each ADR represents 5 Ordinary Shares.

     

     

    CUSIP No.  589492107
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 589492107
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    As of the date of this filing, the Reporting Persons may be deemed to be the beneficial owners of 7,983,851 ADRs (translates to 39,919,255 shares), which amount includes 7,075,000 ADRs (translates to 35,375,000 shares) directly beneficially owned by the Master Fund, and 908,851 ADRs (translates to 4,544,255 shares) directly beneficially owned by Four Pines. The percent of class is determined by dividing the number of Shares beneficially owned by the Reporting Persons by 701,217,089, as reported on Exhibit 99.3 to the Issuer's 6-K filed on September 7, 2023.

    (a) Amount beneficially owned:

    Rock Springs Capital Management LP: 7,983,851 ADRs (translates to 39,919,255 shares)

    Rock Springs Capital LLC: 7,983,851 ADRs (translates to 39,919,255 shares)

    Rock Springs Capital Master Fund LP: 7,075,000 ADRs (translates to 35,375,000 shares)

    (b) Percent of Class:

    Rock Springs Capital Management LP: 5.69%

    Rock Springs Capital LLC: 5.69%

    Rock Springs Capital Master Fund LP: 5.04%

    (c) Number of shares as the which the person has:

     

    (i) Sole power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (ii) Shared power to vote or to direct the vote:

    Rock Springs Capital Management LP: 7,983,851 ADRs (translates to 39,919,255 shares)

    Rock Springs Capital LLC: 7,983,851 ADRs (translates to 39,919,255 shares)

    Rock Springs Capital Master Fund LP: 7,075,000 ADRs (translates to 35,375,000 shares)

     

    (iii) Sole power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (iv) Shared power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 7,983,851 ADRs (translates to 39,919,255 shares)

    Rock Springs Capital LLC: 7,983,851 ADRs (translates to 39,919,255 shares)

    Rock Springs Capital Master Fund LP: 7,075,000 ADRs (translates to 35,375,000 shares)

     

    Item 5. Ownership of Five Percent or Less of a Class

    Not Applicable.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Please see response to Item 2.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 589492107
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Rock Springs Capital Management LP

    By:  Rock Springs Capital LLC, General Partner

           
      By:   Graham McPhail
       

    Name: Graham McPhail

    Title: Member

           
     

    Rock Springs Capital LLC

           
      By:   Graham McPhail
       

    Name: Graham McPhail

    Title: Member

           

     

     
    CUSIP No. 589492107
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2024

     

     

    Rock Springs Capital Management LP

    By:  Rock Springs Capital LLC, General Partner

           
      By:   Graham McPhail
       

    Name: Graham McPhail

    Title: Member

           
     

    Rock Springs Capital LLC

           
      By:   Graham McPhail
       

    Name: Graham McPhail

    Title: Member

           
    Get the next $MREO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MREO

    DatePrice TargetRatingAnalyst
    3/27/2025$7.00Overweight
    Analyst
    12/6/2024$7.00Buy
    Jefferies
    6/13/2024$8.00Outperform
    Robert W. Baird
    10/13/2023$4.00Buy
    BTIG Research
    8/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $MREO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

      Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. "As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-

      5/13/25 7:30:05 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

      Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a

      3/26/25 7:30:36 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

      LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT. A live audio webcast of the fireside chat can be accessed through the Investors section of the Company's website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company's website for two weeks following the live event. About Mereo Bi

      3/5/25 7:30:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Yoskowitz Marc J

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:22 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bender Jeremy

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:14 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shames Daniel

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:06 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Leadership Updates

    Live Leadership Updates

    See more
    • Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

      LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company's Board of Directors, effective immediately. Dr. Mullick joins Mereo's Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geographies, including in rare diseases. "We are very excited to welcome Abdul to the Board at such a pivotal time for the Company," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "His e

      5/17/22 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors

      LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company's Board of Directors, effective immediately. Ms. Hyland has also been appointed to serve on the Audit and Risk Committee of the Board. Ms. Hyland joins Mereo's Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space. "We are very excited to welcome someone with Anne's level of operational and board experience to our Board," said Dr. Denise Scots-Knight, C

      3/1/22 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors

      LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company's Board of Directors, effective September 20, 2021. Dr. Jacquet joins Mereo's Board with over two decades of multidisciplinary experience in the life science industry, including corporate strategy, M&A advisory and value management. "We are delighted to have Pierre joining our board of directors at such an exciting and important time for the Company," said Dr. Denise Scots-Knight, Chief Executive Off

      9/20/21 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Financials

    Live finance-specific insights

    See more
    • Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

      Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. "As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-

      5/13/25 7:30:05 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

      Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a

      3/26/25 7:30:36 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

      LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026. "2024 is off to an exciting start following the completion of enrollment by our partner Ultragenyx in both the Orbit and Cosmic studies of setrusumab in Osteogenesis Imperfecta (OI) along with the continued advancement of the pre-laun

      5/15/24 4:01:44 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 4:18:45 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 3:30:42 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 11:44:32 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Mereo BioPharma with a new price target

      Analyst initiated coverage of Mereo BioPharma with a rating of Overweight and set a new price target of $7.00

      3/27/25 8:18:53 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Mereo BioPharma with a new price target

      Jefferies initiated coverage of Mereo BioPharma with a rating of Buy and set a new price target of $7.00

      12/6/24 7:56:53 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Mereo BioPharma with a new price target

      Robert W. Baird initiated coverage of Mereo BioPharma with a rating of Outperform and set a new price target of $8.00

      6/13/24 7:11:27 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plc

      SCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      5/15/25 10:46:23 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plc

      SCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      5/14/25 4:34:46 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Group plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Mereo BioPharma Group plc (0001719714) (Filer)

      5/14/25 4:30:10 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care